Allopurinol Desensitization: Is There Still a Place in Clinical Practice?

Gout prevalence is rising in many low‐ and middle‐income countries (LMICs). In many LMICs, allopurinol is often the mainstay urate‐lowering therapy (ULT) because alternative ULTs and HLA‐B*58:01 testing are limited or unavailable. Increased allopurinol use may lead to more hypersensitivity reactions; when alternative ULTs are unavailable, allopurinol desensitization may be the only option for selected patients.